Vertex Pharmaceuticals Inc (NASDAQ: VRTX) has reported a loss for its second fiscal quarter (ending June 30) of $-13.92 versus $3.55 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $-1.89 compared to $13.09 a year ago.
Recent Price Action
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock closed at $505.78 on 8/1/24 after a large increase of 2.0%. Moreover, this advance was accompanied by unusually high trading volume at 159% of normal. The stock has risen 3.1% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, VRTX is expected to continue to be an important Value Builder.
Vertex Pharmaceuticals has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Vertex Pharmaceuticals has a slightly negative Appreciation Score of 34 but a good Power Rating of 75, triggering the Neutral Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment